An observational study in Cerebral Arteriovenous Malformation, sponsored by Embo-Flüssigkeiten A.G.. Status unknown at 19 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.
Sponsored by Embo-Flüssigkeiten A.G. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Intracranial Arteriovenous Malformations with a site in France — 6 open to participants now, 6 under way, 1 of them phase 3. Intracranial Arteriovenous Malformations · France.
Among the 12 studies in Intracranial Arteriovenous Malformations with a site in France, this one is one of 3 that started in 2018, is one of 6 observational ones, and was the 4th registered.
43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.
Browse Intracranial Arteriovenous Malformations studies →6 of the 12 studies in Intracranial Arteriovenous Malformations with a site in France are open now. Recruiting first, the newest first:
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Balt Extrusion · Sites in France, Germany, Spain
Ages 2+
Hospices Civils de Lyon · Sites in France
Ages 18+
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 0+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 11 Intracranial Arteriovenous Malformations studies recruiting now, 8 (73%) set no upper age limit and 2 (18%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 2
First in 2006; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is below the median of 140 across 25 observational studies indexed under Intracranial Arteriovenous Malformations.
Median enrollment 66 across the 6 interventional studies, 126 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Embo-Flüssigkeiten A.G. as lead sponsor.
Embo-Flüssigkeiten A.G. has 1 study filed under Intracranial Arteriovenous Malformations — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Intracranial Arteriovenous Malformations with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date. Therefore, the performance of SQUID will be documented and its safety of use will be confirmed in current practice.
Consecutive patients planned for embolization using SQUID to achieve occlusion of a previously untreated bAVM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient planned for one or multiple embolization sessions using SQUID to achieve occlusion of a previously untreated bAVM.*
*Patients with a direct fistula or saccular/flow-related aneurysm previously treated with NBCA and/or coils may be included.
Exclusion Criteria:
Patient with bAVM previously treated by embolization with other devices (Liquid embolic agent, NBCA, particles, and coils).*
*Patients with a direct fistula or saccular / flow-related aneurysm previously treated with NBCA and/or coils may be included.
Patient with multiple bAVM or bAVM associated with dural arteriovenous Fistula*.
*Patients with a direct fistula or saccular / flow-related aneurysm previously treated with NBCA and/or coils may be included.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AVM embolization using SQUID non-adhesive liquid embolic agent
modified Rankin Score (mRS)
mRS is a scale used to measure the degree of handicap or dependence in daily activities of people who have suffered a stroke or other causes of neurological handicap. The scale ranges from 0 to 6, running from perfect health, without symptoms, to death. 0 - No symptoms 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Death.
Time frame: 3 to 6 months after the last embolisation session
Plan to share: No
No publications or documents are linked to this record.
Started May 2018 (actual). Primary completion is estimated for Mar 2022, 46 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intracranial Arteriovenous Malformations →